J
Jeroen Kortekaas
Researcher at Wageningen University and Research Centre
Publications - 83
Citations - 2034
Jeroen Kortekaas is an academic researcher from Wageningen University and Research Centre. The author has contributed to research in topics: Virus & Rift Valley fever. The author has an hindex of 24, co-authored 75 publications receiving 1569 citations. Previous affiliations of Jeroen Kortekaas include Utrecht University.
Papers
More filters
Journal ArticleDOI
Neurotropic virus infections as the cause of immediate and delayed neuropathology.
Martin Ludlow,Jeroen Kortekaas,Christiane Herden,Bernd Hoffmann,Dennis Tappe,Corinna Trebst,Diane E. Griffin,Hannah Brindle,Tom Solomon,Alan S. Brown,Debby van Riel,Katja C. Wolthers,Dasja Pajkrt,Peter Wohlsein,Byron E. E. Martina,Wolfgang Baumgärtner,Georges M. G. M. Verjans,Georges M. G. M. Verjans,Albert D. M. E. Osterhaus,Albert D. M. E. Osterhaus +19 more
TL;DR: Mechanisms that govern neuropathogenesis and immunopathogenesis of viral infections are highlighted, using examples of well-studied virus infections that are associated with these alterations in different populations throughout the world.
Journal ArticleDOI
Creation of a Nonspreading Rift Valley Fever Virus
Jeroen Kortekaas,Nadia Oreshkova,Viviana Cobos-Jiménez,R.P.M. Vloet,Christiaan A. Potgieter,Rob J. M. Moormann +5 more
TL;DR: It is demonstrated that a single intramuscular vaccination with RRPs protects mice from a lethal dose of RVFV and show that RRPs can be used for rapid virus neutralization tests that do not require biocontainment facilities.
Journal ArticleDOI
Heparan sulfate facilitates Rift Valley fever virus entry into the cell
S.M. de Boer,Jeroen Kortekaas,C. A. M. de Haan,Peter J. M. Rottier,Rob J. M. Moormann,Rob J. M. Moormann,Berend Jan Bosch +6 more
TL;DR: It is reported that the glycosaminoglycan heparan sulfate, abundantly present on the surface of most animal cells, is required for efficient entry of Rift Valley fever virus.
Journal ArticleDOI
Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge
S.M. de Boer,S.M. de Boer,Jeroen Kortekaas,Adriaan F.G. Antonis,Jet Kant,J.L. van Oploo,Peter J. M. Rottier,Rob J. M. Moormann,Rob J. M. Moormann,Berend Jan Bosch +9 more
TL;DR: Evaluation of two vaccine candidates based on the viral Gn and Gc envelope glycoproteins produced in a Drosophila insect cell expression system shows absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocAPSid protein-based indirect ELISA.
Journal ArticleDOI
Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector
Jeroen Kortekaas,S.M. de Boer,S.M. de Boer,Jet Kant,R.P.M. Vloet,Adriaan F.G. Antonis,Rob J. M. Moormann +6 more
TL;DR: The production of Gn and Gc is reported by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and it is demonstrated that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice.